FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210342812> ?p ?o ?g. }

• W4210342812 endingPage "3073" @default.
• W4210342812 startingPage "3064" @default.
• W4210342812 abstract "Describe drug utilisation and clinical outcomes of intravitreal anti-VEGF drug and dexamethasone use in the real-world setting in Southern Italy using data from multi-centre study of retinal disease. Clinical data of retinal disease patients treated with anti-VEGF drugs and dexamethasone implant in 6 out-patient ophthalmology centres from Southern Italy were collected by means of an electronic case report form. Patients receiving at least one intravitreal injection/implant of the study drugs were followed for up to two years and described in terms of demographics and clinical characteristics. Drug utilisation patterns were described. A sign-rank test was used to compare clinical data on visual acuity and other ophthalmic parameters from baseline at different follow-up times for each indication. Data from 1327 patients was collected. Most patients were diagnosed with age-related macular degeneration (AMD) (660, 49.7%), followed by diabetic macular oedema (423, 31.9%), retinal vein occlusion (164, 12.3%), and myopic choroidal neovascularization (80, 6.0%). Patients were followed for a median of 10.3 months (interquartile range: 3.6 – 24.7 months). Mean patient age was 69.7 (±10.9) years and 54.2% were males. Ranibizumab (55.4%) and aflibercept (27.5%) were the most commonly used drugs. Baseline visual acuity significantly improved by about 0.05 to 0.1 logMAR at all follow-up times for AMD and RVO but less consistently for the other diseases. Intravitreal ranibizumab use accounted for half of all treatment for retinal diseases in a Southern Italian out-patient setting. Patients treated with anti-VEGF drugs for AMD and RVO in Southern Italy experienced significant improvement in VA." @default.
• W4210342812 created "2022-02-08" @default.
• W4210342812 creator A5004087638 @default.
• W4210342812 creator A5008963285 @default.
• W4210342812 creator A5011800370 @default.
• W4210342812 creator A5015858045 @default.
• W4210342812 creator A5015954067 @default.
• W4210342812 creator A5029796766 @default.
• W4210342812 creator A5046572641 @default.
• W4210342812 creator A5046664524 @default.
• W4210342812 creator A5063403768 @default.
• W4210342812 creator A5070759102 @default.
• W4210342812 creator A5075358428 @default.
• W4210342812 creator A5078719187 @default.
• W4210342812 creator A5078854483 @default.
• W4210342812 creator A5085532664 @default.
• W4210342812 creator A5090000646 @default.
• W4210342812 creator A9999999999 @default.
• W4210342812 date "2022-01-25" @default.
• W4210342812 modified "2023-10-16" @default.
• W4210342812 title "Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southern Italy" @default.
• W4210342812 cites W2001062958 @default.
• W4210342812 cites W2002972720 @default.
• W4210342812 cites W2062694132 @default.
• W4210342812 cites W2105661731 @default.
• W4210342812 cites W2124415048 @default.
• W4210342812 cites W2130501785 @default.
• W4210342812 cites W2134161293 @default.
• W4210342812 cites W2157204458 @default.
• W4210342812 cites W2343042175 @default.
• W4210342812 cites W2732585901 @default.
• W4210342812 cites W2782057573 @default.
• W4210342812 cites W2975797570 @default.
• W4210342812 cites W2988670756 @default.
• W4210342812 cites W3007579267 @default.
• W4210342812 cites W3035825207 @default.
• W4210342812 cites W3088276398 @default.
• W4210342812 cites W3112433314 @default.
• W4210342812 cites W4232181833 @default.
• W4210342812 doi "https://doi.org/10.1177/11206721211073402" @default.
• W4210342812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35075918" @default.
• W4210342812 hasPublicationYear "2022" @default.
• W4210342812 type Work @default.
• W4210342812 citedByCount "0" @default.
• W4210342812 crossrefType "journal-article" @default.
• W4210342812 hasAuthorship W4210342812A5004087638 @default.
• W4210342812 hasAuthorship W4210342812A5008963285 @default.
• W4210342812 hasAuthorship W4210342812A5011800370 @default.
• W4210342812 hasAuthorship W4210342812A5015858045 @default.
• W4210342812 hasAuthorship W4210342812A5015954067 @default.
• W4210342812 hasAuthorship W4210342812A5029796766 @default.
• W4210342812 hasAuthorship W4210342812A5046572641 @default.
• W4210342812 hasAuthorship W4210342812A5046664524 @default.
• W4210342812 hasAuthorship W4210342812A5063403768 @default.
• W4210342812 hasAuthorship W4210342812A5070759102 @default.
• W4210342812 hasAuthorship W4210342812A5075358428 @default.
• W4210342812 hasAuthorship W4210342812A5078719187 @default.
• W4210342812 hasAuthorship W4210342812A5078854483 @default.
• W4210342812 hasAuthorship W4210342812A5085532664 @default.
• W4210342812 hasAuthorship W4210342812A5090000646 @default.
• W4210342812 hasAuthorship W4210342812A9999999999 @default.
• W4210342812 hasConcept C118487528 @default.
• W4210342812 hasConcept C119060515 @default.
• W4210342812 hasConcept C126322002 @default.
• W4210342812 hasConcept C141071460 @default.
• W4210342812 hasConcept C2776403814 @default.
• W4210342812 hasConcept C2776694085 @default.
• W4210342812 hasConcept C2777802072 @default.
• W4210342812 hasConcept C2778257484 @default.
• W4210342812 hasConcept C2778749236 @default.
• W4210342812 hasConcept C2778844676 @default.
• W4210342812 hasConcept C2780347916 @default.
• W4210342812 hasConcept C2780401358 @default.
• W4210342812 hasConcept C2781100027 @default.
• W4210342812 hasConcept C2781359195 @default.
• W4210342812 hasConcept C71924100 @default.
• W4210342812 hasConceptScore W4210342812C118487528 @default.
• W4210342812 hasConceptScore W4210342812C119060515 @default.
• W4210342812 hasConceptScore W4210342812C126322002 @default.
• W4210342812 hasConceptScore W4210342812C141071460 @default.
• W4210342812 hasConceptScore W4210342812C2776403814 @default.
• W4210342812 hasConceptScore W4210342812C2776694085 @default.
• W4210342812 hasConceptScore W4210342812C2777802072 @default.
• W4210342812 hasConceptScore W4210342812C2778257484 @default.
• W4210342812 hasConceptScore W4210342812C2778749236 @default.
• W4210342812 hasConceptScore W4210342812C2778844676 @default.
• W4210342812 hasConceptScore W4210342812C2780347916 @default.
• W4210342812 hasConceptScore W4210342812C2780401358 @default.
• W4210342812 hasConceptScore W4210342812C2781100027 @default.
• W4210342812 hasConceptScore W4210342812C2781359195 @default.
• W4210342812 hasConceptScore W4210342812C71924100 @default.
• W4210342812 hasFunder F4320334846 @default.
• W4210342812 hasIssue "5" @default.
• W4210342812 hasLocation W42103428121 @default.
• W4210342812 hasLocation W42103428122 @default.
• W4210342812 hasOpenAccess W4210342812 @default.
• W4210342812 hasPrimaryLocation W42103428121 @default.
• W4210342812 hasRelatedWork W1964901573 @default.

• next